The Latest Breaking News on Diabetes

Wave Life Sciences Ltd. (NASDAQ:WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for obesity.

Researchers say new compound improves metabolic activity within muscles instead of acting on hunger pathways like Ozempic and Wegovy

They are ‘struggling’ to access support as funding hasn’t kept up with demand

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

A diabetic man previously charged over a crash that killed five following an episode will legally challenge being called as a witness in an inquest.

The U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths

The love hormone, oxytocin, may be able to influence our relationship with food, researchers say

About three million devices are affected, though many may be expired or already used

The World Health Organisation says GLP‑1 weight‑loss jabs, originally for diabetes, can also treat obesity.

GLP-1 medication, such as Wegovy, was added to the list of ‘essential’ medicines by the World Health Organization in September

WHO urges countries to make drugs such as Mounjaro more accessible to people and asks drugs companies to lower prices